Povetacicept Data Validate APRIL/BAFF Inhibition in IgAN and pMN, With James Tumlin, MD - HCPLive4 hours ago • Google News
ProMIS (NASDAQ: PMN) reports PMN310 Phase 1b >85% enrolled; interim data Q2 2026 - Stock TitanYesterday • Google News
Vertex Unveils Positive 48-Week Data For Povetacicept In IgAN And PMN - Nasdaq4 days ago • Google News